Toulouse

• IMPACT-CTEPH Ended
  2024-513672-17-00 4 2021-06-14 Inoperable Chronic thromboembolic pulmonary hyperTension
• A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product … Ended
  2024-512123-37-00 5 2021-05-27 Parkinson's disease
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended
  2023-506918-45-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended
  2023-506919-18-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
• Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With ORL Cancer in Remission and With Sequellae … Ended
  2024-515510-41-00 4 2021-04-28 Head and neck cancer
• A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the … Ended
  2022-501188-42-00 4 2021-04-15 Early Alzheimer's Disease
• MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non … Ended
  2022-501252-28-00 4 2021-04-15 Non Small Cell Lung cancer
• BiCAR Therapy - A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas after CAR T-cells th … Ended
  2023-508301-25-00 4 2021-03-26 Relapse/Refractory Lymphomas
• “A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatini … Ended
  2023-508001-25-00 4 2021-03-15 Metastatic Thymic Carcinoma & B3-thymoma.
• EFRAIM II _ Empirical steroids and/or antifungals treatment of immunocompromised patients with acute respiratory failure of uknown origin: a … Ended
  2024-514344-82-00 5 2021-02-18 patients with acute respiratory failure from undetermined etiology
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• A Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab Plus Pemetrexed and C … Ended
  2022-502031-20-00 10 2020-12-17 Non-squamous non-small cell lung cancer (NSCLC)
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2) Ended
  2023-506724-85-00 5 2020-11-19 Migraine
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thro … Ended
  2023-510107-22-00 5 2020-10-27 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• IFCT-1802 SAVIMMUNE: Immunotherapy in Patient With Poor General Condition Ended
  2024-515943-44-00 4 2020-10-14 Non small cell lung cancer
• A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with r … Ended
  2024-518265-10-01 1 2020-06-03 Relapse/ refractory acute Leukemia
• Pragmatic management of progressive disease in idiopathic pulmonary fibrosis Ended
  2024-511427-34-00 5 2020-02-20 idiopathic pulmonary fibrosis
• Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Trip … Ended
  2022-500418-24-00 10 2020-01-17 Locally Recurrent Inoperable or Metastatic Triple Negative Breast Canc
• Tepotinib plus osimertinib in osimertinib-relapsed MET amplified NSCLC Ended
  2024-512005-87-00 4 2019-11-07 Lung Cancer
• A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage … Ended
  2024-516201-23-00 4 2019-08-26 Lung Cancer, NSCLC
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 6 2019-07-25 Rheumatoid Arthritis
• Comparative multicenter randomized study of aflibercept versus placebo in macular telangiectasia type 1 Ended
  2024-511885-35-00 5 2019-07-03 macular telangiectasia type 1

Showing 601–624 of 642 trials